intestinal antiinflammatory agents	is a	drug class
intestinal antiinflammatory agents	treats	inflammatory bowel disease
inflammatory bowel disease	includes	Crohn's disease
inflammatory bowel disease	includes	ulcerative colitis
intestinal antiinflammatory agents	contains	aminosalicylates
aminosalicylates	example	mesalamine
mesalamine	mechanism	inhibits prostaglandins
prostaglandins	role	inflammation mediators
intestinal antiinflammatory agents	contains	corticosteroids
corticosteroids	example	prednisone
prednisone	side effect	osteoporosis
intestinal antiinflammatory agents	contains	immunomodulators
immunomodulators	example	azathioprine
azathioprine	mechanism	suppresses immune system
intestinal antiinflammatory agents	contains	biologic therapies
biologic therapies	target	TNF-α
TNF-α	role	proinflammatory cytokine
biologic therapies	example	infliximab
infliximab	administration	intravenous
intestinal antiinflammatory agents	reduces	intestinal inflammation
intestinal inflammation	causes	abdominal pain
intestinal antiinflammatory agents	improves	diarrhea
diarrhea	symptom of	IBD
intestinal antiinflammatory agents	prevents	disease flares
disease flares	require	hospitalization
intestinal antiinflammatory agents	combined with	antibiotics
antibiotics	treat	bacterial infections
intestinal antiinflammatory agents	contraindicated in	bowel obstruction
bowel obstruction	complication of	IBD
intestinal antiinflammatory agents	monitored by	colonoscopy
colonoscopy	detects	mucosal healing
intestinal antiinflammatory agents	affects	gut microbiota
gut microbiota	influences	immune response
intestinal antiinflammatory agents	interacts with	NSAIDs
NSAIDs	exacerbate	IBD
intestinal antiinflammatory agents	requires	dose titration
dose titration	prevents	toxicity
intestinal antiinflammatory agents	alternative to	surgery
surgery	indicated for	complications
intestinal antiinflammatory agents	improves	quality of life
quality of life	measured by	questionnaires
intestinal antiinflammatory agents	prescribed by	gastroenterologists
gastroenterologists	specialize in	digestive disorders
intestinal antiinflammatory agents	stored at	room temperature
intestinal antiinflammatory agents	formulation	oral tablets
oral tablets	alternative	suppositories
suppositories	used for	distal colitis
intestinal antiinflammatory agents	metabolized in	liver
liver	function tests	monitor toxicity
intestinal antiinflammatory agents	excreted via	kidneys
kidneys	affected by	nephrotoxicity
intestinal antiinflammatory agents	research focus	new biologics
new biologics	target	IL-12/23
IL-12/23	role	inflammatory pathways
intestinal antiinflammatory agents	cost	expensive
expensive drugs	barrier to	adherence
intestinal antiinflammatory agents	combined with	probiotics
probiotics	modify	gut flora
intestinal antiinflammatory agents	contraindicated in	allergies
allergies	manifest as	rash
intestinal antiinflammatory agents	pregnancy category	varies
pregnancy	requires	special consideration
intestinal antiinflammatory agents	affects	nutrient absorption
nutrient absorption	impacts	malnutrition
intestinal antiinflammatory agents	interacts with	warfarin
warfarin	requires	INR monitoring
intestinal antiinflammatory agents	alternative	dietary therapy
dietary therapy	includes	low-FODMAP
intestinal antiinflammatory agents	requires	compliance
compliance	improves	outcomes
intestinal antiinflammatory agents	compared to	placebo
placebo	effect	psychological
intestinal antiinflammatory agents	development	clinical trials
clinical trials	phases	I-IV
intestinal antiinflammatory agents	patent	time-limited
patent expiry	allows	generics
intestinal antiinflammatory agents	brand examples	Asacol
Asacol	contains	mesalamine
intestinal antiinflammatory agents	mechanism	NF-κB inhibition
NF-κB	regulates	inflammation
intestinal antiinflammatory agents	adverse effect	pancreatitis
pancreatitis	symptom	abdominal pain
intestinal antiinflammatory agents	contraindicated in	renal impairment
renal impairment	requires	dose adjustment
intestinal antiinflammatory agents	pharmacokinetics	first-pass effect
first-pass effect	reduces	bioavailability
intestinal antiinflammatory agents	alternative administration	enema
enema	delivers	local therapy
intestinal antiinflammatory agents	efficacy	endoscopic improvement
endoscopic improvement	correlates with	remission
intestinal antiinflammatory agents	cost-effectiveness	debated
cost-effectiveness	considers	QALYs
intestinal antiinflammatory agents	withdrawal	cautious
withdrawal	may cause	relapse
intestinal antiinflammatory agents	monitoring	blood tests
blood tests	check	liver enzymes
intestinal antiinflammatory agents	education	pharmacist role
pharmacist	advises	administration
intestinal antiinflammatory agents	storage	moisture-sensitive
moisture	degrades	drug stability
